Press Release

Rheumatoid Arthritis Therapeutics Market 2019 Global Analysis, Industry Size, Share Leaders, Current Status by Major Key vendors and Trends by Forecast to 2025

Rheumatoid Arthritis Therapeutics Market report covers top players as Pfizer Inc., Amgen Inc., Johnson & Johnson Services, Inc., CELGENE CORPORATION, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd, UCB S.A., Eli Lilly and Company, Gilead Sciences, Inc., Other players

According to the report, the global rheumatoid arthritis therapeutics market is anticipated to exhibit 4.6% CAGR and reach valuation of US$ 33,958.4 Mn in 2025 from US$ 23,822.5 Mn in 2017.

Exhibiting a high prevalence for rheumatoid arthritis, North America is forecast to lead the global rheumatoid arthritis therapeutics market in a recent report. In a report, titled “Rheumatoid Arthritis Therapeutics: Global Market Analysis, Insights and Forecast, 2018-2025”, Fortune Business Insights identifies numerous factors enabling growth in the market.

Get Sample PDF Brochure:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/rheumatoid-arthritis-therapeutics-market-100488

Some of the other key players operating in the global rheumatoid arthritis therapeutics market are Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Eli Lilly and Company, UCB S.A., Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Celgene Corporation, and Johnson & Johnson Services, Inc.

North America to Lead Global Market with Rising Prevalence of Rheumatoid Arthritis

The North America market was worth US$ 9,929.6 Mn in 2017. It is expected to show steady rise owing to the rising prevalence of rheumatoid arthritis and increasing awareness about this disorder. Adding to that, governments of North America are investing huge sums for improving the healthcare and medical facilities in the region. This is helping the rheumatoid arthritis therapeutics market to grow at an impressive pace in North America.

On the other side, the demand for rheumatoid arthritis treatment is likely to grow at a considerable pace in Asia Pacific. This is owing to the entry of new drugs, especially biologics, for the treatment of rheumatoid arthritis in the market. This, coupled with expansion of healthcare and medical infrastructure in emerging nations, is likely to help rheumatoid arthritis therapeutic market in Asia Pacific gain more momentum.

Biologics Segment to Account for Highest Market Share

In terms of product type, the biologics segment is anticipated to hold the highest share in the market in terms of revenue during the forecast period. In 2017, the biologics segment held 87.6% of the rheumatoid arthritis therapeutics market. This is because biologics targeting specific components of the immune response system help to slow down the rate of progression of arthritis in the patient. They also help in improving the physical functionality of patients and are cost efficient as compared to other treatment methods, which helps to increase the demand for biologics in the market.

Presence of expensive drugs for rheumatoid arthritis treatment, coupled with, favorable reimbursement policies are factors propelling the global market. Developing countries are making efforts to improve their medical infrastructure in order to provide medical aid for diseases such as chronic arthritis and other chronic diseases and this is another key factor helping the market to grow.

Increasing Number of Medical Professionals Facilitating Rheumatoid Arthritis Treatment

Rise in geriatric population is a key factor enabling growth in the market. The prevalence of arthritis is considerably high among aged population, which is why a rise in their number is expected to bode well for the overall market. In case of rheumatoid arthritis, improvement in diagnostic procedures is favoring growth of the global market for rheumatoid arthritis. Furthermore, the market is expected to gain from the spread of various awareness programs and increasing number of skilled healthcare professionals.

Browse Complete Report:

https://www.fortunebusinessinsights.com/industry-reports/rheumatoid-arthritis-therapeutics-market-100488

In 2017, AbbVie Inc., emerged dominant in the global rheumatoid arthritis therapeutics market. At present there are numerous market players operating in the market, out of which about ten players hold 80% of the market. In order to gain competitive advantage, some of the leading companies are focusing on investing increasingly towards research and development of novel therapeutics.

View Related Reports:

Blood Glucose Meters Market to reach US$ 15,415.6 Mn by 2026, exhibiting a CAGR of 9.6% | Fortune Business Insights

Botulinum Toxin Market to Rise Impressively at 8.0% CAGR, Huons’ Latest Launch of Botulinum Toxin Products to Enable Market Growth, says Fortune Business Insights

Cannabis Market to Exhibit 32.6% CAGR; Legalization of Medical Marijuana in Most Countries to Propel Growth, Says Fortune Business Insights

 

Tags

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close